Advertisements


Spark Therapeutics: Inside The Dramatic FDA AdCom Meeting

Analysts at Cantor Fitzgerald continue to hold a bullish stance on Spark Therapeutics Inc (NASDAQ: ONCE) after the U.S. Latest Ratings for ONCE.....»»

Category: blogSource: benzingaOct 13th, 2017

All The Sell-Side Responses To Spark Therapeutics" Strong AdCom Meeting On Luxturna

On Thursday afternoon, and FDA advisory panel recommended approval of Spark Therapeutics Inc (NASDAQ: ONCE)’s Luxturna treatment for inherited blindness. Latest Ratings for ONCE.....»»

Category: blogSource: benzingaOct 13th, 2017

Spark Therapeutics Ignites Excitement Over Unanimous Adcom Panel Vote

Spark Therapeutics Ignites Excitement Over Unanimous Adcom Panel Vote.....»»

Category: topSource: seekingalphaOct 17th, 2017

Credit Suisse Weighs In Ahead Of PTC Therapeutics" Thursday AdCom Panel For Translarna

PTC Therapeutics, Inc. (NASDAQ: PTCT) is already experiencing some major volatility Tuesday ahead of its upcoming AdCom meeting for Duchenne muscular dystrophy drug candidate Translarna on Thursday. Latest Ratings for PTCT DateFir.....»»

Category: blogSource: benzingaSep 26th, 2017

Spark Therapeutics announces multiple presentations at ASH Annual Meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active trader.....»»

Category: blogSource: theflyonthewallNov 30th, 2016

TG Therapeutics Gives Update on FDA Meeting

The agency says an application for accelerated approval of TG-––…– based on the overall response rate would be a review issueRelated Stocks: TGTX,.....»»

Category: worldSource: nytOct 17th, 2017

4 Biotechs Boosted By Spark Therapeutic"s FDA News

Spark Therapeutics Inc (NASDAQ: ONCE) saw its name transition from Wall Street headlines to Main Street headlines after a U.S. Food and Drug Administration voted favorably on the company's therapy. read more.....»»

Category: blogSource: benzingaOct 16th, 2017

Therapy to treat blindness may become reality soon

The approval of Spark Therapeutics Inc's Luxturna therapy would pave the way for new payment models for drugs, particularly in the US.....»»

Category: topSource: business-standardOct 14th, 2017

Is Spark Therapeutics’ Luxturna a Game Changer?

Shares of Spark Therapeutics saw a handy gain to close out the week after the FDA recommended approval of Luxturna......»»

Category: blogSource: 247wallstOct 13th, 2017

Gene Therapies: A Foot in the Door

Spark Therapeutics scored a big win for the gene therapy category. Here are the other companies that might benefit......»»

Category: blogSource: barronsOct 13th, 2017

Spark: A Big Win for Gene Therapy. So Why Is It Falling?

Shares of Spark Therapeutics are down today, despite winning the recommendation of a FDA advisory panel for its experimental gene therapy......»»

Category: blogSource: barronsOct 13th, 2017

3 Highlights From A Spark Therapeutics Fireside Chat

Analysts at Jefferies hosted a fireside chat-themed conversation with Spark Therapeutics Inc (NASDAQ: ONCE) to discuss the company's successes from Thursday's FDA panel. Latest Ratings for ONCE.....»»

Category: blogSource: benzingaOct 13th, 2017

Spark Therapeutics shares jump 7.5% after FDA committee backs blindness treatment

Shares of Spark Therapeutics Inc. surged 7.5% premarket Friday, after a U.S. Food and Drugs Administration advisory committee recommended approval of the company's gene therapy treatment for a rare eye disease that causes blindness. .....»»

Category: topSource: marketwatchOct 13th, 2017

FDA advisory panel recommends approval of Spark Therapeutics" gene therapy

A Food and Drug Administration advisory committee voted Thursday to recommend approval of Spark Therapeutics’ application for its experimental gene therapy developed to treat vision loss caused by an inherited retinal disease. The company, which .....»»

Category: topSource: bizjournalsOct 12th, 2017

Spark Therapeutics shares halted as FDA committee reviews gene therapy treatment for eye disease

Spark Therapeutics Inc. shares were halted Thursday as a U.S. Food and Drugs Administration advisory committee meets to review the company's gene therapy treatment for patients with vision loss caused.....»»

Category: topSource: marketwatchOct 12th, 2017

Spark Therapeutics shares halted as FDA advisory committee reviews gene therapy

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchOct 12th, 2017

The Unusual Reason PTC Therapeutics, Inc. Is Bouncing Back Today

Investors are clinging to hopes that yesterday's advisory committee meeting wasn't as bad as it seemed......»»

Category: topSource: foxnewsSep 29th, 2017

Goldman: Wal-Mart Is Worth a Bet

Goldman Sachs says the retailing giant’s upcoming analyst meeting should spark a stock rally......»»

Category: topSource: barronsSep 27th, 2017

Barron"s Picks And Pans: Spark Therapeutics, Six Flags, Oracle And More

This weekend's Barron's cover story three stock picks on the fo.....»»

Category: blogSource: benzingaSep 24th, 2017

The inside story of how a $12 billion deal for a revolutionary cancer treatment came together (KITE, GILD)

ReutersOne of the most attention-catching biotech deals of the year slotted into place after a fateful July meeting that didn't directly have to do with either company, a new filing shows.  In August, Gilead Sciences said it would sp.....»»

Category: topSource: businessinsiderSep 6th, 2017

Here"s Why Spark Therapeutics Inc. Surged 23.5% in August

Revealing positive clinical trial data for a bleeding-disorder candidate increased confidence for the company's proprietary gene therapy development platform......»»

Category: topSource: foxnewsSep 6th, 2017